Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 3

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 3
---
 OUR SECURITIES.

Our American Depositary Shares (“ADSs”) are listed on the Nasdaq Global Market under the symbol “CNTB.” On
June 9, 2025, the last reported sale price of our ADSs on the Nasdaq Global Market was $0.78 per share.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is , 2025.

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                 |     |  1 |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS     |     |  2 |
| WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY 
 REFERENCE                                             |     |  3 |
| ENFORCEMENT OF CIVIL LIABILITIES                      |     |  5 |
| THE COMPANY                                           |     |  6 |
| RISK FACTORS                                          |     | 15 |
| USE OF PROCEEDS                                       |     | 16 |
| DESCRIPTION OF SHARE CAPITAL                          |     | 17 |
| DESCRIPTION OF AMERICAN DEPOSITARY SHARES             |     | 27 |
| DESCRIPTION OF DEBT SECURITIES                        |     | 37 |
| DESCRIPTION OF WARRANTS                               |     | 45 |
| DESCRIPTION OF PURCHASE CONTRACTS                     |     | 47 |
| DESCRIPTION OF UNITS                                  |     | 48 |
| GLOBAL SECURITIES                                     |     | 49 |
| PLAN OF DISTRIBUTION                                  |     | 53 |
| LEGAL MATTERS                                         |     | 55 |
| EXPERTS                                               |     | 55 |

EXPLANATORY NOTE This registration statement contains:

| • |     | A base prospectus, which covers the offering, issuance and sales by us of up to $300,000,000 in the aggregate 
 of our securities from time to time in one or more offerings; and                                             |

| • |     | A sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate                                                                                
 offering price of up to $150,000,000 of the ADSs that may be issued and sold from time to time under a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”). |

The base prospectus immediately follows this explanatory note. The specific terms of any securities to be